Skip to main content
. 2021 Jul 8;31(10):1072–1087. doi: 10.1038/s41422-021-00528-3

Fig. 6. MVC, as a CCR5 antagonist, combines with TMZ to effectively impair GBM growth.

Fig. 6

a Schematic diagram of the combined treatment of MVC and TMZ in tumor-bearing mice. MVC (100 mg/kg, i.p.) was given for 4 consecutive days since Day 14 and TMZ (5 mg/kg, i.p.) was given for 3 consecutive days since Day 15 after tumor implantation. The growth of GBM-2 xenografts was monitored by bioluminescence imaging on Day 14, Day 17 and Day 21 after tumor implantation. b, c In vivo bioluminescence images (b) and quantification (c) of tumor growth of GBM-2 xenografts treated with TMZ, MVC or vehicle on Day 14, Day 17 and Day 21 after tumor implantation. ns, not significant. *P < 0.05; **P < 0.01. n = 5 for each group. d Kaplan–Meier survival analysis of mice bearing GBM-2 xenografts treated with TMZ, MVC or vehicle. n = 5 for each group. e, f Immunofluorescence staining (e) and quantification (f) of γ-H2AX-positive cells (green) in GBM-2 xenografts treated with TMZ, MVC or vehicle. ns, not significant. *P < 0.05; **P < 0.01. Scale bars, 25 μm. g, h Immunofluorescence staining (g) and quantification (h) of phosphorylated DNA-PKcs (Ser2056, red) in GBM-2 xenografts treated with TMZ, MVC or vehicle. ns, not significant. *P < 0.05. Scale bars, 25 μm.